Beam Therapeutics is down a bit on the day, funds flowing out kept the price down -2.54% since yesterday.
Currently BEAM isn't at a clear support/resistance line that seems tradable. Momentum wise Beam Therapeutics , has been oscillating up and down but hasn't shown much directional energy that would be predictive to the near future. BEAM might find some support at the 21.17 level, buyers might push the price back up from here. But it's not very clear what will happen.
The analysts are pretty neutral on Beam Therapeutics right now, so not much useful information here. The current Analysts Sentiment Score is 0.66. Most companies range between (-200 to 200).
Here's a break down of the latest rating changes. Royal Bank of Canada gave a boost to their price target and moved to $35.00 from $27.00 on 2024-02-28. On 2024-02-28 Barclays increased their price target by 61.54% to $42.00. On 2024-02-27 there was confirmation of the previous rating by Wedbush which was Outperform and also increased their price target by 18.75% to $57.00. JPMorgan Chase & Co. announced an upgrade on 2024-01-29 from Neutral to Overweight and provided a price target boost 5.26% to $40.00 from $38.00. Bank of America released a downgrade on 2023-12-15 from Buy to Neutral and added a price target of $35.00. Jefferies Financial Group reiterated a rating of Buy on 2023-12-08 and they lowered their price target by -60% to $30.00 from a previous target of $75.00. William Blair reiterated a rating of Outperform on 2023-10-31. On 2023-10-20 there was a downgrade announced by SVB Leerink from Outperform to Market Perform and dropped their 1 year price target to $20.00 which is down from $75.00. Cantor Fitzgerald released a downgrade on 2023-10-20 from Overweight to Neutral. Leerink Partnrs downgraded from Outperform to Market Perform on 2023-10-20.
| Company | Ratings Score
?
Composite analyst sentiment score
|
Positive Ratings | Negative Ratings | Boost Price Target | Lower Price Target |
|---|---|---|---|---|---|
| BEAM | 0.66 | 1.6 | -1.25 | 1.67 | -0.71 |
| Company | YOY Growth Score (typical -20 to +20) | Revision Directions (-6 to +6) |
|---|---|---|
| BEAM | 0.00 | 0.00 |
We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.
| Company | Short Score (typical 1-15)
?
We take into account several different measures and attributes of short interest to create a composite sentiment score. typical range (0 - 30)
|
Short Interest | Days to Cover | Rate of Change | Shares Short |
|---|---|---|---|---|---|
| BEAM | 18.78 | %19.0657 | 16.3 | 10.956 | 15100000 |
Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.
| Ticker | Social Sentiment(1-10) |
|---|---|
| BEAM |
| Company | Score | 1 Day% | 5 Day | 1 Month | 3 Month | 6 Month | 1 Year | RSI | 3mo S-momo ? | 6mo S-momo | 1yr S-momo | Resistance ? | Support | Demark Sell ? | Demark Buy | Short Interest Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDIT | Editas Medicine, Inc. Com | 1.61 | -4.35 | 15.79 | 23.20 | 12.41 | -52.02 | 0.00 | 83 | -25.34 | -35.42 | -51.29 | -71477.53 | -4058.41 | 0 | 0 | 0 |
| NTLA | Intellia Therapeutics, In | 1.47 | 6.00 | 8.29 | 8.42 | -21.72 | -40.41 | -65.57 | 72 | -89.45 | -127.81 | -126.94 | -46273.80 | -2202.78 | 0 | 0 | 10.4627 |
| TWST | Twist Bioscience Corporat | 1.43 | -3.41 | -7.48 | -19.13 | -27.49 | -23.32 | -35.75 | 62 | -20.71 | -18.79 | -21.62 | 169.39 | -1989.73 | 0 | 0 | 23.3961 |
| VCYT | Veracyte, Inc. | 1.32 | -1.61 | -1.98 | -7.71 | -27.01 | -22.44 | 22.78 | 63 | -5.20 | -4.72 | -3.93 | 173.53 | -1812.39 | 0 | 0 | 4.97884 |
| CRSP | CRISPR Therapeutics AG | 1.3 | -1.32 | 2.79 | -2.47 | -17.84 | -18.34 | -31.27 | 62 | -33.18 | -51.49 | -71.84 | -12972.98 | -2336.98 | 0 | 0 | 15.3247 |
| RCKT | Rocket Pharmaceuticals, I | 1.28 | -1.69 | -3.40 | -8.32 | -36.42 | -56.88 | -72.69 | 72 | -89.83 | -106.61 | -198.27 | -26163.63 | -2009.95 | 125 | 0 | 9.12889 |
| MTLS | Materialise NV | 1.22 | -1.02 | -1.39 | 14.58 | -13.03 | -25.91 | 1.83 | 74 | -14.74 | -16.37 | -22.86 | -7587.43 | -2920.69 | 150 | 0 | 0 |
How to use: use the research links to research the asset. Then simply type in a score for each category between (01, 02, 03, 04, 05). 05 being the most bullish and 01 being the most bearish. It will automatically calculate the average and combine it with the technical score to create an overall score to rank prospects by. You can also type notes into each field.
